[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342699-105":59,"doc-detail-342699-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","circulating-tumour-dna-based-molecular-residual-disease-detection-in-resectable-cancers-a-systematic-review-and-meta-analysis","Circulating tumour DNA-Based molecular residual disease detection in resectable cancers - a systematic review and meta-analysis","","Background: Circulating tumour DNA (ctDNA)-based molecular residual disease (MRD) testing is used to assess recurrence risk, yet evidence differs on its predictive efficacy for recurrence and overall survival and on test sensitivity/specificity. Methods: Prospective studies were searched in PubMed, Embase, Cochrane, and Scopus (Jan 1, 2013 to Sept 10, 2023), excluding retrospective designs. A pooled hazard ratio for recurrence and OS and pooled sensitivity/specificity were estimated using random-effects models. Findings: 80 studies supported higher recurrence/OS hazard with ctDNA positivity and longitudinal tests outperformed landmark tests. Conclusion: Postoperative ctDNA testing predicts recurrence and OS, with improved performance from longitudinal monitoring.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/circulating-tumour-dna-based-molecular-residual-disease-detection-in-resectable-cancers-a-systematic-review-and-meta-analysis/342699/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/circulating-tumour-dna-based-molecular-residual-disease-detection-in-resectable-cancers-a-systematic-review-and-meta-analysis/342699.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of the systematic review and meta-analysis?","Question",{"text":112,"@type":113},"To evaluate how ctDNA-based MRD detection predicts recurrence and overall survival in patients with resectable cancers, and to compare sensitivity/specificity between landmark and longitudinal testing.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which studies were included and how were they selected?",{"text":117,"@type":113},"The review systematically searched PubMed, Embase, Cochrane, and Scopus for prospective studies or randomized controlled trials that collected blood samples prospectively, excluding retrospective studies.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about longitudinal versus landmark ctDNA tests?",{"text":121,"@type":113},"Longitudinal testing showed higher sensitivity, AUSROC, and diagnostic odds ratio than landmark testing when comparing ctDNA+ versus ctDNA- patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342699,1790167897,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Articles   \nCirculating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis  \nJiachun Zheng,a Chuling Qin,b Qianxi Wang,b Dongbo Tian,a,∗ and Zisheng Chena,∗∗  \naDepartment of Respiratory and Critical Care Medicine, Afﬁliated Qingyuan Hospital of Guangzhou Medical University, Qingyuan People’s Hospital, Qingyuan, 511518, China  \nbGuangzhou Medical University, Guangzhou, 511436, China  \nSummary  \nBackground Circulating tumour DNA (ctDNA)-based molecular residual disease (MRD) detection technology has been widely used for recurrence evaluation, but there is no agreement on the efﬁcacy of assessing recurrence and overall survival (OS) prognosis, as well as the sensitivity and speciﬁcity of landmark detection and longitudinal detection.  \nMethods We systematically searched Pubmed, Embase, Cochrane, and Scopus for prospective studies or randomized controlled trials that collected blood samples prospectively. The search period was from Jan 1, 2013, to Sept 10, 2023 . We excluded retrospective studies. The primary endpoint was to assess the hazard ratio (HR) between circulating tumour DNA positive (ctDNA+) and negative (ctDNA-) for recurrence-free survival incidence (RFS), disease-free survival (DFS), progression-free survival (PFS), event-free survival (EFS), time to recurrence (TTR), distant metastasis-free survival (DMFS) or OS in patients with resectable cancers. We calculated the pooled HR of recurrence and OS and 95% conﬁdence interval (CI) in patients with resected cancers using a random-effects model. Pooled sensitivity and speciﬁcity were estimated using the bivariate random effects model.  \nFindings This systematic review and meta-analysis returned 7578 records, yielding 80 included studies after exclusion. We found that the HR of recurrence across all included cancers between patients with ctDNA+ and ctDNA-was 7.48 (95% CI 6.39–8.77), and the OS was 5.58 (95% CI 4.17–7.48) . We also found that the sensitivity, area under the summary receiver operating characteristic curve (AUSROC) and diagnostic odds ratio (DOR) of longitudinal tests were higher than that of landmark tests between patients with ctDNA+ and ctDNA- (0.74, 95% CI 0.68–0.80 vs 0.50, 95% CI 0.46–0.55; 0.88 vs. 0.80; 25.70, 95% CI 13.20–45.40 vs. 9.90, 95% CI 7.77–12.40) .  \nInterpretation Postoperative ctDNA testing was a signiﬁcant prognosis factor for recurrence and OS in patients with resectable cancers. However, the overall sensitivity of ctDNA-MRD detection could be better. Longitudinal monitoring can improve the sensitivity, AUSROC, and DOR.  \nFunding Special fund project for clinical research of Qingyuan People’s Hospital (QYRYCRC2023006), plan on enhancing scientiﬁc research in GMU (GZMU-SH-301) .  \nCopyright © 2024 The Author(s) . Published by Elsevier B.V. This is an open access article under the CC BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)).  \nKeywords: Molecular residual disease (MRD); Circulating tumour DNA; Surgery; Adjuvant therapy; Meta-analysis  \nIntroduction  \nCancer remains a major public health problem worldwide. According to Cancer Statistics, 2023,1 until 2020, in America, colorectal cancer (CRC), lung cancer, pancreatic adenocarcinoma (PAAD), bladder cancer (BLCA), melanoma, breast cancer (BC), gastric cancer  \n(GC), hepatocellular carcinoma (HCC), ovarian cancer (OV) and esophageal carcinoma (ESCA) predicted for 7.81%, 12.17%, 3.27%, 4.20%, 4.98%, 15.35%, 1.35%, 2.10%, 1.01%, 1.10% of new cases in 2023, and the mortality rates were 8.62%, 20.84%, 8.29%, 2.74%, 1.31%, 7.17%, 1.83%, 4.82%, 2.18%, 2.64%,  \n*Corresponding author.  \n**Corresponding author.  \nE-mail addresses: [2682105044@qq.com](2682105044@qq.com) (D. Tian), [502463784@qq.com](502463784@qq.com) (Z. Chen).  \neBioMedicine 2024;103: 105109 Published Online xxx [https://doi.org/10](https://doi.org/10) . 1016/j.ebiom.2024 . 105109  \n[www.thelancet.com Vol](www","cbCaij6HAwFVtamQ","https://ap.wps.com/l/cbCaij6HAwFVtamQ","pdf",746483,13,"English","# Summary\n## Background\n## Methods\n## Findings\n## Interpretation\n## Funding\n# Research in context\n## Evidence before this study\n## Added value of this study\n## Implications of all the available evidence","[{\"question\":\"What was the main objective of the systematic review and meta-analysis?\",\"answer\":\"To evaluate how ctDNA-based MRD detection predicts recurrence and overall survival in patients with resectable cancers, and to compare sensitivity/specificity between landmark and longitudinal testing.\"},{\"question\":\"Which studies were included and how were they selected?\",\"answer\":\"The review systematically searched PubMed, Embase, Cochrane, and Scopus for prospective studies or randomized controlled trials that collected blood samples prospectively, excluding retrospective studies.\"},{\"question\":\"What did the results show about longitudinal versus landmark ctDNA tests?\",\"answer\":\"Longitudinal testing showed higher sensitivity, AUSROC, and diagnostic odds ratio than landmark testing when comparing ctDNA+ versus ctDNA- patients.\"}]","Circulating tumour DNA-Based molecular residual disease detection in resectable cancers - a systematic review and meta-analysis | PDF",1790047757,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/702c76701d28f2a9e889ca1c04607741.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c81d67db4d60c0d2a1469f0bf6bd14c3.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a30bdedbcc41b639a004d91040fd297.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/021a0f61559a95299d1735e8a8b0c0d7.webp",980,1306]